Abstract Body

Background

As use of long-acting (LA) ART without HBV activity increases, optimizing HBV prevention in PWH is increasingly important. HepB-CpG, an adjuvanted HBV vaccine, has superior immunogenicity to HepB-alum. Understanding regional variation in revaccination outcomes may inform tailored vaccine strategies.

Methods

BEeHIVe (ACTG5379, PMID 39616603) enrolled PWH from 41 sites in Africa, Asia, Brazil, and USA. Participants with nonresponse to prior HBV vaccine were randomized 1:1:1 to receive 2 or 3 doses HepB-CpG or 3 doses HepB-alum (dosed 0,1 or 0,1,6mo). Regional analyses were conducted to examine differences in past vaccination history and seroprotection response (SPR,anti-HBs≥10mIU/mL) to study vaccines across the regions. Kruskal-Wallis (for continuous variables) and Fisher’s exact (for categorical variables) tests, and logistic regression models with stepwise variable selection (for associations between SPR and host factors) were used.

Results

Of 1098 screened, 561(51%) eligible participants were randomized at 41 sites in: Africa (n=117, Botswana, Kenya, Malawi, South Africa, Uganda), Asia (n=95, Philippines, Thailand, Vietnam), Brazil (n=37) and USA (n=312). Median age at enrollment was 46 yrs (range 18–70), with significant regional variation(p<0.0001): youngest in Africa (median 26 yrs) and oldest in USA (53 yrs). Age at first HBV vaccination varied across regions(p<0.0001). The first vaccination age was as infants(<1 yr) for 50% in Africa, compared to 19%, 14% and 4% in Asia, Brazil, and USA, respectively. Prior HBV vaccine doses ranged from 1 to 12: 3 doses in 54%, 1–2 doses in 22%, and ≥4 doses in 24%. Notably, none in Africa had received ≥4 doses, compared to 4% in Asia, 43% in Brazil, and 36% in USA(p<0.0001).  Across all regions, HepB-CpG achieved higher primary SPRs than HepB-alum, particularly with 3 doses except Brazil, where sample size was small. HepB-alum responses varied, being highest in Africa and lowest in the USA; this trend was more evident at the end of study. Final regression model identified Black race (which varied by region) to be predictive of primary SPR, along with Hep-CpG, younger age and higher CD4.

Conclusions

HepB-CpG consistently achieved higher SPR than HepB-alum across regions. Participant age and timing of initial HBV vaccination likely contribute to regional SPR differences. These findings underscore the importance of tailoring HBV prevention strategies to regional testing and vaccination practices, particularly in the context of expanding LA ART use.

Table or Figure